Brainomix

Brainomix, a leader in AI-powered imaging tools for stroke and lung fibrosis, has secured an additional £4.8 million (approximately $6.5 million) in its Series C financing, bringing the total to £18.8 million (around $25.4 million). The funding, led by Parkwalk Advisors and Hostplus, along with new investor Modi Ventures, will enhance the deployment of its AI platforms, Brainomix 360 Stroke and e-lung, across U.S. hospitals, improving patient care in stroke and lung disease management.

Brainomix, an Oxford-based company specializing in AI-powered imaging, has secured an additional £4.8 million in a Series C extension, raising its total funding to £18.8 million. The funding, led by Parkwalk and Hostplus with new support from Modi Ventures, aims to enhance its growth in the U.S. and improve customer support. Brainomix's platforms, brainomix 360 stroke and e-lung, address critical imaging needs for stroke and lung fibrosis, enabling faster and more accurate treatment decisions.